Clinical and Experimental Reproductive Medicine

  • 제40권2호
  • /
  • Pages.100-105
  • /
  • 2013
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome

  • Hwang, Kyu Ri (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Choi, Young Min (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Kim, Jin Ju (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Chae, Soo Jin (Maria Fertility Hospital) ;
  • Park, Kyung Eui (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Jeon, Hye Won (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Ku, Seung Yup (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Kim, Seok Hyun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Kim, Jung Gu (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Moon, Shin Yong (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
  • 투고 : 2013.03.09
  • 심사 : 2013.05.24
  • 발행 : 2013.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: The aim of this study was to investigate the effect of insulin sensitizing agents on hormonal and metabolic parameters as well as menstrual patterns in women with polycystic ovary syndrome (PCOS). Methods: One hundred and twenty-three patients with PCOS were included. Metformin was administered to patients at 1,500 mg or 1,700 mg daily for 3 months. If the patients had no improvement of the menstrual cycle or metformin-related adverse effects developed, the patients changed medication to a daily dose of either 15 mg pioglitazone or up to 45 mg. Then resumption of a regular menstrual cycle or recovery of ovulation was evaluated. Hormonal and metabolic profiles were compared between the response and non-response group to insulin sensitizing agents. Results: One hundred and five patients with PCOS were treated with metformin for 3 months. Forty-eight patients (45.7%) showed improvement of menstrual cycle regularity after 3 months of metformin use, whereas 57 patients (54.3%) had no change. The mean free testosterone measured after 3 months of treatment was significantly lower in metformin responders than in non-responders. The other parameters did not differ between the groups. Of the 23 patients who used pioglitazone for 3 to 6 months, 19 patients (82.6%) showed improvement in their menstrual cycles. Conclusion: Metformin treatment seems to be effective for the improvement of menstrual cyclicity irrespective of insulin resistance in women with PCOS. When metformin related adverse effect occurred, pioglitazone would be effective for aiding the resumption of the menstrual cycle.

키워드

참고문헌

  1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9. https://doi.org/10.1210/jc.2003-032046
  2. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-10. https://doi.org/10.1172/JCI118126
  3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774-800.
  4. Li M, Youngren JF, Dunaif A, Goldfine ID, Maddux BA, Zhang BB, et al. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002;87:4088-93. https://doi.org/10.1210/jc.2002-020363
  5. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006;30:13-7. https://doi.org/10.1385/ENDO:30:1:13
  6. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54. https://doi.org/10.1016/0026-0495(94)90209-7
  7. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46.
  8. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo- controlled trial. J Clin Endocrinol Metab 2002;87:569-74. https://doi.org/10.1210/jcem.87.2.8261
  9. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13. https://doi.org/10.1016/S0015-0282(02)04554-5
  10. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007;196:402.e1-10. https://doi.org/10.1016/j.ajog.2006.12.025
  11. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007; 157:669-76. https://doi.org/10.1530/EJE-07-0294
  12. Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod 2010;25:1005-13. https://doi.org/10.1093/humrep/dep466
  13. Koenen TB, Tack CJ, Kroese JM, Hermus AR, Sweep FC, van der Laak J, et al. Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. J Clin Endocrinol Metab 2009; 94:4453-7. https://doi.org/10.1210/jc.2009-0517
  14. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:3835-40. https://doi.org/10.1210/jc.2003-031737
  15. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210-8. https://doi.org/10.1093/humrep/deg264
  16. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G, et al. Responses of serum androgen and in sulin resistance to metformin and pioglitazone in obese, insulinresistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360-5. https://doi.org/10.1210/jc.2004-1965
  17. Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2009;94:469-76. https://doi.org/10.1210/jc.2008-1133
  18. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003;18: 1618-25. https://doi.org/10.1093/humrep/deg343
  19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  20. Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008;23:1924-31. https://doi.org/10.1093/humrep/den239
  21. Hwang KR, Choi YM, Choi DS, Baek KH, Jeon HW, Bae KB, et al. Effect of metformin treatment and insulin resistance in patients with polycystic ovary syndrome. Korean J Obstet Gynecol 2004; 47:1949-53.
  22. Ferrannini E, Balkau B. Insulin: in search of a syndrome. Diabet Med 2002;19:724-9. https://doi.org/10.1046/j.1464-5491.2002.00794.x
  23. Hucking K, Watanabe RM, Stefanovski D, Bergman RN. OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself. Obesity (Silver Spring) 2008; 16:1938-45. https://doi.org/10.1038/oby.2008.336
  24. Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril 2012;97:18-22. https://doi.org/10.1016/j.fertnstert.2011.11.036
  25. Pirwany IR, Yates RW, Cameron IT, Fleming R. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum Reprod 1999;14:2963-8. https://doi.org/10.1093/humrep/14.12.2963
  26. Koo YA, Shin SY, Yoon BK, Choi D. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Gynecol Endocrinol 2007; 23:461-7. https://doi.org/10.1080/09513590701492689
  27. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007;13:527-37. https://doi.org/10.1093/humupd/dmm026
  28. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008;93:792-800. https://doi.org/10.1210/jc.2007-1736

피인용 문헌

  1. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran vol.12, pp.None, 2013, https://doi.org/10.1186/1477-7827-12-89
  2. Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome vol.5, pp.1, 2013, https://doi.org/10.1186/2040-2392-5-4
  3. Comparison of Levels of Androgenic Hormones in various Phenotypes of Polycystic Ovarian Syndrome in High School Girls aging 14 to 18 Years vol.8, pp.1, 2013, https://doi.org/10.5005/jp-journals-10006-1382
  4. Comparison of Levels of Androgenic Hormones in various Phenotypes of Polycystic Ovarian Syndrome in High School Girls aging 14 to 18 Years vol.8, pp.1, 2013, https://doi.org/10.5005/jp-journals-10006-1382
  5. A Dietary Medium-Chain Fatty Acid, Decanoic Acid, Inhibits Recruitment of Nur77 to the HSD3B2 Promoter In Vitro and Reverses Endocrine and Metabolic Abnormalities in a Rat Model of Polycystic Ovary Sy vol.157, pp.1, 2013, https://doi.org/10.1210/en.2015-1733
  6. The impact of parental history of type 2 diabetes on hyperinsulinemia and insulin resistance in subjects from central Mexico vol.11, pp.suppl2, 2017, https://doi.org/10.1016/j.dsx.2017.07.012
  7. Acupuncture treatment for insulin sensitivity of women with polycystic ovary syndrome and insulin resistance: a study protocol for a randomized controlled trial vol.18, pp.1, 2017, https://doi.org/10.1186/s13063-017-1854-2
  8. Insulin resistance improvement by cinnamon powder in polycystic ovary syndrome: A randomized double‐blind placebo controlled clinical trial vol.32, pp.2, 2013, https://doi.org/10.1002/ptr.5970
  9. Effects of placebo‐controlled insulin‐sensitizing drugs on hormonal parameters in polycystic ovary syndrome patients: A network meta‐analysis vol.119, pp.3, 2013, https://doi.org/10.1002/jcb.26410
  10. Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Coptis chinensis Franchin Polycystic Ovary Syndrome vol.2021, pp.None, 2013, https://doi.org/10.1155/2021/6651307
  11. Progression to prediabetes or diabetes in young Korean women with polycystic ovary syndrome: A longitudinal observational study vol.94, pp.5, 2013, https://doi.org/10.1111/cen.14416